Answers are grounded in this paper and cite their sources.
Oral hyperpigmentation is an infrequent phenomenon reported in the literature as a side effect that may be seen with the administration of certain chemotherapy agents such as doxorubicin. Given the under reported nature of mucosal hyperpigmentation, treating providers are frequently unaware of this benign presentation and thus may pursue unnecessary testing. The exact pathophysiology and mechanism of action of this phenomenon is poorly understood; however, it is hypothesized that some chemotherapy drugs may trigger increased melanin deposition. With regard to management, clinical monitoring for eventual resolution status post chemotherapy without additional therapy is sufficient. Increased familiarity with this uncommon side effect will prevent invasive testing and undue stress to the patient. We present a case of tongue hyperpigmentation that occurred during administration of doxorubicin and cyclophosphamide in the neoadjuvant setting for management of stage IIIA(cT2,cN1,M0) hormone receptor positive breast cancer, which resolved without intervention after completion of chemotherapy course.
No takes yet. Share an insight, caveat, or question.
Rupert et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: